Aphios® Corporation has been self-funded to date with Founders’ capital, employee stock ownership, grants and contracts from the National Institutes of Health and other institutions, collaborative and contract research with emerging biotechnology and multinational companies, and product sales to biotechnology companies and research chemical distribution houses, such as Millipore Sigma-Aldrich. We are actively seeking investors and strategic corporate partners for:
• Aphios Pharma LLC is developing cannabis-based, FDA approved drugs for opioid addiction, chemotherapy induced peripheral neuropathic pain (CIPNP) and other central and peripheral nervous system disorders
• Aphios International LLC is developing a pathogen reduction technology platform, CFI™ for human plasma, plasma products, immunoglobulins, recombinant biologics, monoclonal antibodies and medical devices such as PPEs, N95 masks and single use devices.
• Amylon™ LLC is developing a novel alpha-secretase modulator, APH-1104, for mild to moderate Alzheimer’s disease and other CNS disorders such as Down’s syndrome and glaucoma.
• Zindol® LLC is developing Zindol® for chemotherapy-induced nausea and vomiting (CINV), and other nausea/vomiting-induced conditions caused by pregnancy, motion sickness, and drugs.